What is Sutro Biopharma's return on equity?

Sutro Biopharma (STRO) reported return on equity of -234.2% in Q4 2024.

What is the long-term trend for Sutro Biopharma's return on equity?

Over 3 years (2020 to 2024), Sutro Biopharma's return on equity has grown at a 150.2% compound annual growth rate (CAGR), from -14.9% to -234.2%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Sutro Biopharma STRO Return on equity

Return on equity at other companies

PfizerPFE

10.6%—

Gilead SciencesGILD

43.2%+10.7pp

RegenxbioRGNX

-196.4%-288pp

Nuvectis Pharma, Inc.NVCT

-154.4%+79.4pp

XencorXNCR

-29.8%-2.7pp

AnaptysBio, Inc.ANAB

-343.8%-1,012pp

Other financials

Income statement

See full

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

See full

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

See full

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

See full

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

See full

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

See full

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Calculated from Sutro Biopharma’s reported figures.

net income/total stockholders equity=-234.2%

Based on trailing twelve months.

The official record: Sutro Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Sutro Biopharma's return on equity?: Sutro Biopharma (STRO) reported return on equity of -234.2% in Q4 2024.
What is the long-term trend for Sutro Biopharma's return on equity?: Over 3 years (2020 to 2024), Sutro Biopharma's return on equity has grown at a 150.2% compound annual growth rate (CAGR), from -14.9% to -234.2%.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.